Repeated ketamine anesthesia during the neonatal period impairs hippocampal neurogenesis and long-term neurocognitive function by inhibiting mfn2-mediated mitochondrial fusion in neural stem cells
It has gained significant interest for its regenerative properties and potential benefits in medical research purposes
Common formulations include: BPC-157: 10 mg per vial in typical KLOW formulations TB-500: 10 mg per vial in typical KLOW formulations GHK-Cu: 50 mg per vial in typical KLOW formulations (highest proportion) KPV: 10 mg per vial in typical KLOW formulations Total blend: 80 mg combined peptide content Individual component research dosing: BPC-157 studies: 10 mcg/kg most common in rat models (range: 1-1000 mcg/kg) TB-500 studies: 1-10 mg/kg typical range in rodent research GHK-Cu studies: 0.01-100 nanomolar in cell culture
For this reason, BPC-157 is particularly useful in addressing digestive issues, such as ulcers, leaky gut and IBS
We encourage each patient to prepare and ask questions, and raise any concerns they may have
Research Applications Lipid metabolism and lipolysis research Adipose tissue biology investigations Fat oxidation and energy expenditure studies Cartilage and bone repair models Comparative hGH fragment analog studies Quality Specifications Purity: 98% (HPLC verified) Compound: AOD-9604 Molecular Weight: 1815.1 Da Form: Lyophilized powder Origin: Made in the USA Testing: Third-party tested in a US laboratory Storage: -20C, protect from light COA: Batch-specific, ISO-accredited laboratory Frequently Asked Questions Q: What is AOD-9604 used for
